Company Overview of Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. develops and commercializes biofluid based in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of oncologic, metabolic, and other diseases. It offers exosome-based minimally-invasive and body fluid molecular diagnostics. The company focuses on commercializing high sensitivity/specificity RNA in vitro diagnostic assays for use in disease recurrence monitoring and as companion diagnostics for use with targeted molecular therapies. The company has strategic collaborations with QIAGEN and Addario Lung Cancer Medical Institute. The company was formerly known as Exosome Theranostics, Inc. and changed its name to Exosome Diagnost...
840 Memorial Drive
Cambridge, MA 02139
Founded in 2008
Key Executives for Exosome Diagnostics, Inc.
Vice President of Business Development
Director of Development and Services
Compensation as of Fiscal Year 2014.
Exosome Diagnostics, Inc. Key Developments
Exosome Diagnostics, Inc. and Addario Lung Cancer Medical Institute Announce Collaboration to Accelerate Development of Plasma-Based Lung Cancer Diagnostics
Jan 9 15
Exosome Diagnostics, Inc. announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The collaboration will support validation of Exosome Diagnostics ALK and T790M lab developed tests (LDTs) planned to launch in 2015 and help advance future development of the company’s ALK and T790M in vitro diagnostic (IVD) kits. Exosome Diagnostics ALK and T790M tests have the potential to provide clinicians with real-time, precise molecular insights to help inform individualized treatment decisions for patients with lung cancer upon initial diagnosis and throughout the course of treatment. Exosome Diagnostics novel technology platform enables the development of tests that can analyze stable, high-quality exosomal RNA (exoRNA), representing a potentially important advance given that many known cancer mutations, such as gene arrangements and splice variants, are difficult or impossible to detect utilizing circulating DNA analysis.
Exosome Diagnostics Appoints Thomas McLain as Chief Executive Officer, Effective July 23, 2014
Aug 4 14
Exosome Diagnostics announced the appointment of Thomas McLain as its chief executive officer, effective July 23, 2014. Mr. McLain most recently was the CEO of Vermillion.
Exosome Diagnostics Appoints Vincent J. O'Neill as Chief Medical Officer
Jun 3 14
Exosome Diagnostics announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalised medicine, most recently as global head personalised of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalised medicine strategy built the internal infrastructure and designed best practice protocols. He also created alliances and agreements with diagnostic testing laboratories and in vitro diagnostic companies. Prior to working at Sanofi, Dr. O'Neill managed the clinical development programs of several oncology therapeutic candidates, including biomarker development, at both Genentech and GlaxoSmithkline. He was instrumental in the expanded approval of products such as Avastin(R) and Tarceva(R) at Genentech. At GlaxoSmithkline, he managed the signal transduction discovery unit from which the first Investigative New Drug (IND) application and clinical trial, including patient selection strategy, of an MEK inhibitor (Mekinist(R)) was conducted.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 3, 2014